Clinical Trials Logo

Anemia, Hemolytic clinical trials

View clinical trials related to Anemia, Hemolytic.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT05676697 Terminated - Clinical trials for Autoimmune Hemolytic Anemia

PI3K Delta Inhibitor in Relapsed / Refractory Autoimmune Hemolytic Anemia Patients After Receiving Two or More Lines of Therapy

Start date: January 13, 2023
Phase: Phase 1
Study type: Interventional

This is a prospective, multicenter, single-arm, pilot study. The aim of this study is to evaluate the efficacy and safety of Linperlisib, the PI3K delta inhibitor for autoimmune hemolytic anemia patients who failed the second line therapy.

NCT ID: NCT04964323 Terminated - Anemia Clinical Trials

Pyruvate Kinase (PK) Deficiency Global Longitudinal Registry: Patient-Reported Outcomes (PRO)

PKD
Start date: July 2, 2021
Phase:
Study type: Observational [Patient Registry]

The primary objective of this study is to understand and characterize the health-related quality of life (HRQoL) and disease burden of adult participants with PK deficiency receiving routine clinical care. This study is an observational (i.e., noninterventional), longitudinal, multicenter, global registry for participants with PK deficiency, a rare nonspherocytic hemolytic anemia. This study will be open for enrollment for 2 years and all enrolled participants will be followed prospectively for up to 96 weeks. Data will be collected from participants who have provided informed consent and authorization pursuant to applicable laws and regulations.

NCT ID: NCT04661033 Terminated - Clinical trials for Warm Autoimmune Hemolytic Anemia (wAIHA)

Safety, Pharmacokinetics, and Efficacy of Subcutaneous Isatuximab in Adults With Warm Autoimmune Hemolytic Anemia (wAIHA)

Start date: September 9, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

Primary Objectives: - Part A: To evaluate the safety and tolerability of subcutaneous injections of isatuximab in adults with wAIHA - Part B: To evaluate the efficacy of the selected dose in adults with wAIHA Secondary Objectives: - Part A (Cohorts 2 and 3 only) - To evaluate the efficacy of isatuximab in adults with wAIHA - To evaluate the durability of response to isatuximab and time to response - To evaluate the impact of isatuximab treatment on fatigue Part B - To evaluate the safety and tolerability of isatuximab in adults with wAIHA - To evaluate the durability of response to isatuximab and time to response - To evaluate the impact of isatuximab treatment on fatigue Parts A (all Cohorts) and B - To evaluate the effect of isatuximab on markers of hemolysis - To characterize the pharmacokinetic profile of isatuximab in adults with wAIHA - To evaluate the immunogenicity of isatuximab

NCT ID: NCT04253236 Terminated - Clinical trials for Warm Autoimmune Hemolytic Anemia

To Assess the Efficacy and Safety of RVT-1401 in the Treatment of Warm Autoimmune Hemolytic Anemia (ASCEND-WAIHA).

ASCEND-WAIHA
Start date: August 11, 2020
Phase: Phase 2
Study type: Interventional

This is a Phase 2 non-randomized, open-label study to investigate the efficacy, safety and tolerability of RVT-1401 in patients with Warm Autoimmune Hemolytic Anemia.

NCT ID: NCT03075878 Terminated - Clinical trials for Warm Autoimmune Hemolytic Anemia

A Safety Study of SYNT001 in Participants With Warm Autoimmune Hemolytic Anemia (WAIHA)

Start date: January 10, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This main study objective was to evaluate the safety and tolerability of intravenous (IV) SYNT001 (ALXN1830) in participants with WAIHA.